Siga Technologies Inc. (NASDAQ:SIGA – Get Free Report) saw unusually large options trading on Wednesday. Stock investors acquired 1,200 call options on the stock. This represents an increase of 1,438% compared to the average daily volume of 78 call options.
Analyst Upgrades and Downgrades
SIGA has been the topic of a number of research analyst reports. Wall Street Zen downgraded Siga Technologies from a “strong-buy” rating to a “hold” rating in a research report on Saturday, November 15th. Weiss Ratings reissued a “hold (c-)” rating on shares of Siga Technologies in a research report on Monday. One analyst has rated the stock with a Hold rating, Based on data from MarketBeat.com, the stock has an average rating of “Hold”.
Get Our Latest Analysis on Siga Technologies
Institutional Trading of Siga Technologies
Siga Technologies Stock Up 0.6%
NASDAQ:SIGA opened at $6.27 on Friday. Siga Technologies has a 52 week low of $4.95 and a 52 week high of $9.62. The stock’s fifty day moving average is $6.81 and its two-hundred day moving average is $7.44. The stock has a market capitalization of $448.64 million, a price-to-earnings ratio of 6.14 and a beta of 0.98.
Siga Technologies (NASDAQ:SIGA – Get Free Report) last posted its quarterly earnings data on Thursday, November 6th. The company reported ($0.09) earnings per share (EPS) for the quarter. Siga Technologies had a net margin of 43.22% and a return on equity of 35.23%. The firm had revenue of $2.62 million during the quarter. On average, sell-side analysts expect that Siga Technologies will post 1.04 EPS for the current fiscal year.
About Siga Technologies
Siga Technologies, Inc (NASDAQ: SIGA) is a specialty pharmaceutical company focused on the development, manufacturing and commercialization of medical countermeasures for public health emergencies and biological threats. The company’s flagship product, TPOXX® (tecovirimat), is the first and only antiviral approved by the U.S. Food and Drug Administration for the treatment of smallpox. Siga has entered into procurement and development contracts with U.S. government agencies, including the Biomedical Advanced Research and Development Authority (BARDA) and the Department of Defense, to supply TPOXX® for the Strategic National Stockpile.
Founded in 2002, Siga has built a pipeline of therapies targeting high-consequence pathogens such as smallpox, plague and other potential biothreat agents.
Featured Articles
- Five stocks we like better than Siga Technologies
- Put $1,000 into this stock by Jan 1 [Not NVDA]
- Turn your “dead money” into $306+ monthly (starting this month)
- Washington prepares for war
- Strange Crystal Metal Outperforms Silicon Up to 100X
- 33,000% boom from weird new “AI Fuel?”
Receive News & Ratings for Siga Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Siga Technologies and related companies with MarketBeat.com's FREE daily email newsletter.
